Terms: = Lung cancer AND NUP214, ENSG00000126883, 8021, MGC104525, D9S46E, RP11-544A12_7, N214, CAIN, P35658, CAN AND Clinical Outcome
603 results:
1. Remote Monitoring and Data Collection for Decentralized clinical Trials.
Daly B; Brawley OW; Gospodarowicz MK; Olopade OI; Fashoyin-Aje L; Smart VW; Chang IF; Tendler CL; Kim G; Fuchs CS; Beg MS; Zhang L; Legos JJ; Duran CO; Kalidas C; Qian J; Finnegan J; Pilarski P; Keane H; Shen J; Silverstein A; Wu YL; Pazdur R; Li BT
JAMA Netw Open; 2024 Apr; 7(4):e246228. PubMed ID: 38607626
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic impact of age in advanced non-small cell lung cancer patients undergoing first-line checkpoint inhibitor immunotherapy and chemotherapy treatment.
Huang X; Wu S; Chen S; Qiu M; Zhao Y; Wei J; He J; Zhao W; Tan L; Su C; Zhou S
Int Immunopharmacol; 2024 May; 132():111901. PubMed ID: 38554448
[TBL] [Abstract] [Full Text] [Related]
3. Spreading Through Air Spaces And Thinking About lung Metastases.
M Castro P; Rei J; Silva C; Miranda J; Guerra M
Port J Card Thorac Vasc Surg; 2023 Oct; 30(3):31-35. PubMed ID: 38499034
[TBL] [Abstract] [Full Text] [Related]
4. Investigating the prognostic value of constructing disulfidptosis-related gene models for lung adenocarcinoma patients.
Luo M; Liu RZ; Li YJ; Zhang SD; Wu ZY
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):9569-9585. PubMed ID: 37916324
[TBL] [Abstract] [Full Text] [Related]
5. Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy.
Lin R; Mallick AB; Wang ZX; Brown SA; Lu B; Jiang W
Diagn Pathol; 2023 Oct; 18(1):116. PubMed ID: 37865792
[TBL] [Abstract] [Full Text] [Related]
6. clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan.
Baba T; Kusumoto M; Kato T; Kurihara Y; Sasaki S; Oikado K; Saito Y; Endo M; Fujiwara Y; Kenmotsu H; Sata M; Takano T; Kato K; Hirata K; Katagiri T; Saito H; Kuwano K
Int J Clin Oncol; 2023 Dec; 28(12):1585-1596. PubMed ID: 37787866
[TBL] [Abstract] [Full Text] [Related]
7. De Novo Design and Development of a Nutrient-Rich Perfusate for Ex Vivo lung Perfusion with Cell Culture Models.
Huang L; Vellanki RN; Zhu Z; Wouters BG; Keshavjee S; Liu M
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685927
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy of Tyrosine Kinase Inhibitors in Primary Driver-Gene-Positive Combined Small-Cell lung cancer: A Retrospective Study.
Shi Z; Wei J; Sun W; Zeng X; Zhou H; Song Z
Clin Lung Cancer; 2023 Dec; 24(8):717-725.e1. PubMed ID: 37482500
[TBL] [Abstract] [Full Text] [Related]
9. Programmed Death Ligand -1 and Gene Mutation Characterization of lung Malignancies in Patients at a Rural Hospital in Central India.
Kanthali M; Mamgain P; Dhawan P; Bhagwat G; Patel S; Purohit MR
Asian Pac J Cancer Prev; 2023 Jun; 24(6):1855-1861. PubMed ID: 37378912
[TBL] [Abstract] [Full Text] [Related]
10. Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study.
Nicholson BD; Oke J; Virdee PS; Harris DA; O'Doherty C; Park JE; Hamady Z; Sehgal V; Millar A; Medley L; Tonner S; Vargova M; Engonidou L; Riahi K; Luan Y; Hiom S; Kumar H; Nandani H; Kurtzman KN; Yu LM; Freestone C; Pearson S; Hobbs FR; Perera R; Middleton MR
Lancet Oncol; 2023 Jul; 24(7):733-743. PubMed ID: 37352875
[TBL] [Abstract] [Full Text] [Related]
11. POTEE mutation as a potential predictive biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
Li Y; Yang Q; Liu Y; Yi H; Ju Y; Qi G
Invest New Drugs; 2023 Aug; 41(4):556-563. PubMed ID: 37318657
[TBL] [Abstract] [Full Text] [Related]
12. Pretreatment 18-FDG-PET/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy.
Grambozov B; Kalantari F; Beheshti M; Stana M; Karner J; Ruznic E; Zellinger B; Sedlmayer F; Rinnerthaler G; Zehentmayr F
Radiother Oncol; 2023 Aug; 185():109728. PubMed ID: 37301259
[TBL] [Abstract] [Full Text] [Related]
13. Comparison of outcome after stereotactic ablative radiotherapy of patients with metachronous lung versus primary lung cancer.
Benzaquen J; Bondiau PY; Otto J; Marquette CH; Berthet JP; Naghavi AO; Schiappa R; Hannoun-Levi JM; Padovani B; Doyen J
Radiat Oncol; 2023 Jun; 18(1):97. PubMed ID: 37287020
[TBL] [Abstract] [Full Text] [Related]
14. Type 2 Diabetes Mellitus and Efficacy outcomes from Immune Checkpoint Blockade in Patients with cancer.
Cortellini A; D'Alessio A; Cleary S; Buti S; Bersanelli M; Bordi P; Tonini G; Vincenzi B; Tucci M; Russo A; Pantano F; Russano M; Stucci LS; Sergi MC; Falconi M; Zarzana MA; Santini D; Spagnolo F; Tanda ET; Rastelli F; Giorgi FC; Pergolesi F; Giusti R; Filetti M; Lo Bianco F; Marchetti P; Botticelli A; Gelibter A; Siringo M; Ferrari M; Marconcini R; Vitale MG; Nicolardi L; Chiari R; Ghidini M; Nigro O; Grossi F; De Tursi M; Di Marino P; Queirolo P; Bracarda S; Macrini S; Inno A; Zoratto F; Veltri E; Spoto C; Vitale MG; Cannita K; Gennari A; Morganstein DL; Mallardo D; Nibid L; Sabarese G; Brunetti L; Perrone G; Ascierto PA; Ficorella C; Pinato DJ
Clin Cancer Res; 2023 Jul; 29(14):2714-2724. PubMed ID: 37125965
[TBL] [Abstract] [Full Text] [Related]
15. lung cancer surgery for patients with reduced left ventricular ejection fraction: clinical outcomes and long-term survival.
Kim MS; Hong TH; Yun J; Kim HK; Choi YS; Kim J; Shim YM; Cho YH; Cho JH
Eur J Cardiothorac Surg; 2023 May; 63(5):. PubMed ID: 37099712
[TBL] [Abstract] [Full Text] [Related]
16. RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and clinical outcome.
Nishio M; Paz-Ares L; Reck M; Nakagawa K; Garon EB; Popat S; Ceccarelli M; Graham HT; Visseren-Grul C; Novello S
Clin Lung Cancer; 2023 Jul; 24(5):415-428. PubMed ID: 37076395
[TBL] [Abstract] [Full Text] [Related]
17. Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.
Torasawa M; Yoshida T; Takeyasu Y; Shimoda Y; Tateishi A; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Takahashi K; Ohe Y
Cancer Med; 2023 Jun; 12(11):12388-12401. PubMed ID: 37062059
[TBL] [Abstract] [Full Text] [Related]
18. One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy.
Hager T; Borchert S; Wessolly M; Mathilakathu A; Mairinger E; Kollmeier J; Mairinger T; Hegedus B; Greimelmaier K; Wohlschlaeger J; Herrmann K; Mairinger FD
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047331
[TBL] [Abstract] [Full Text] [Related]
19. PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection.
Navarese EP; Podhajski P; Gurbel PA; Grzelakowska K; Ruscio E; Tantry U; Magielski P; Kubica A; Niezgoda P; Adamski P; Junik R; Przybylski G; Pilaczyńska-Cemel M; Rupji M; Specchia G; Pinkas J; Gajda R; Gorog DA; Andreotti F; Kubica J
J Am Coll Cardiol; 2023 Jan; 81(3):224-234. PubMed ID: 36653090
[TBL] [Abstract] [Full Text] [Related]
20. clinical outcome of Brazilian patients with non-small cell lung cancer in early stage harboring rare mutations in epidermal growth factor receptor.
Machado-Rugolo J; Baldavira CM; Prieto TG; Olivieri EHR; Fabro AT; Rainho CA; Castelli EC; Ribolla PEM; Ab'Saber AM; Takagaki T; Nagai MA; Capelozzi VL
Braz J Med Biol Res; 2023; 55():e12409. PubMed ID: 36629526
[TBL] [Abstract] [Full Text] [Related]
[Next]
